Evidence map›Paper›PMID 28689331›Full record

ReviewCurrent hypertension reports2017

Pathophysiology and Current Clinical Management of Preeclampsia.

Lorena M Amaral, Kedra Wallace, Michelle Owens, Babbette LaMarca

Abstract readReview
In one paragraph

Review in Current hypertension reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 4 pooled it
16.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 4 syntheses or guidelines pooled it, 276 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Article
  8. Article
  9. The pathophysiology of pre-eclampsia.Nature reviews. Nephrology · 2026
    Review
  10. Hyperadhesive von Willebrand Factor Contributes to Pathogenesis of Preeclampsia.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  11. Article
  12. Exploring the Role of Kisspeptin in Polycystic Ovary Syndrome and Its Associated Pregnancy Complications.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Review
  13. Immune Cells in Preeclampsia.International journal of molecular sciences · 2025
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Role of Immune Cells in Mediating the Effect of Lipids on Preeclampsia.Reproductive sciences (Thousand Oaks, Calif.) · 2025
    Article
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Lorena M AmaralDepartment of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS, USA.
Kedra WallaceDepartment of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, MS, USA.
Michelle OwensDepartment of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, MS, USA.
Babbette LaMarcaDepartment of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS, USA. bblamarca@umc.edu.
University of Mississippi Medical Center · US

Funding

Hypertension and Cardiorenal Research Training ProgramT32HL105324 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI Joey P. Granger · 2010 to 2026
$7.8M
The Kidney, Hypertension, Pregnancy and InflammationR01HD067541 · NICHD · UNIVERSITY OF MISSISSIPPI MED CTR · PI LAMARCA, BABBETTE · 2011 to 2020
$3.1M
NHLBI NIH HHS T32 HL105324NICHD NIH HHS R01 HD067541
6 · The paper itself

Abstract

Preeclampsia is characterized by blood pressure greater than 140/90 mmHg in the second half of pregnancy. This disease is a major contributor to preterm and low birth weight babies. The early delivery of the baby, which becomes necessary for maintaining maternal well-being, makes preeclampsia the leading cause for preterm labor and infant mortality and morbidity. Currently, there is no cure for this pregnancy disorder. The current clinical management of PE is hydralazine with labetalol and magnesium sulfate to slow disease progression and prevent maternal seizure, and hopefully prolong the pregnancy. This review will highlight factors implicated in the pathophysiology of preeclampsia and current treatments for the management of this disease.

Indexed as

Delivery, ObstetricAntihypertensive AgentsBlood PressureCalcium Channel BlockersEndothelium, VascularFemaleHumansHydralazineInfant, Low Birth WeightInfant, NewbornInflammationIschemiaLabetalolMagnesium SulfatePlacentaPre-EclampsiaAntihypertensive AgentsCalcium Channel BlockersHydralazineLabetalolMagnesium SulfateEndothelial dysfunctionInflammationPlacental ischemiaPreeclampsia

Identifiers

PMID28689331
PMCPMC5916784
OpenAlexW2727740730

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.